Prognia
Drug Database
🇪🇺EU · EMARefusedATC: M09AX15Orphan Medicine

Elevidys(delandistrogene moxeparvovec)

Muscular Dystrophy, Duchenne

Marketing Authorisation Holder: Roche Registration GmbH

INN: delandistrogene moxeparvovec

Indication

Treatment of ambulatory patients aged 3 to 7 years old with Duchenne muscular dystrophy

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Elevidys — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.